Aclara, Virologic, Exelixis, CombiMatrix, Furuno Electric, American Academy of Microbiology, Caliper Life Sciences, Ciphergen | GenomeWeb

Aclara Posts Uptick in Q2 Revenues as Losses Decrease; Acquisition By Virologic Still On

Aclara Biosciences last week reported an uptick in second-quarter revenue amid significantly decreased R&D spending and a narrowed net loss.

The company, which is slated to be acquired by ViroLogic during the fourth quarter [see 6/304 PGx Reporter], generated $515,000 in receipts for the three months ended June 30 compared with $405,000 in the year-ago quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.